Essex Bio-Technology (HK:1061) has released an update.
Essex Bio-Technology Limited has received approval from China’s National Medical Products Administration to commercialize its preservative-free unit-dose Sodium Hyaluronate Eye Drops (0.1%) in the Chinese market. This product is designed to provide relief for various eye conditions, including dry eye syndrome and injuries from surgery or contact lens use. The approval is a significant step for the company as it expands its portfolio of eye care solutions in China.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.